A sequential-panel, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of a single dose of Merck 0657nI Staphylococcus aureus vaccine in healthy adults 18-55 years of age.
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2014
At a glance
- Drugs V-710 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 04 Dec 2006 New trial record.